Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients

Souza, Alexandre Wagner Silva de; Mariz, Henrique Ataíde; Neto, E.T. Reis; Arraes, Anne Elizabeth Diniz; Silva, Neusa Pereira da; Sato, Emília Inoue

doi:10.1007/s10067-008-1056-0

Cited by 22 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an experimental study, co‐exposure to O 3 plus PM 2.5 induced acute decreases in BP in all rats (Wagner et al, ). SO 2 , NO 2 , or PM 2.5 exposure causes a decrease in antioxidant defenses (Liu et al, ) and dysregulation of the NO synthase pathways, which induced the production of the vasoconstrictor ET‐1 (Bouthillier et al, ; Vincent et al, ; Weis and Cooke, ; de Souza et al, ). Additionally, epidemiological studies suggest that proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), inducible nitric oxide synthase (iNOS), cyclooxygenase‐2 (COX‐2), and interleukin‐6 (IL‐6), are abnormal in patients with congestive heart failure (CHF) and myocardial infarction ( Mann, ; Yndestad et al, ; Yun et al, ; Han et al, ).…”

Section: Introductionmentioning

confidence: 99%

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5

Zhang

et al. 2015

Environ. Toxicol.

View full text Add to dashboard Cite

SO , NO , and PM are typical air pollutants produced during the combustion of coal. Increasing evidence indicates that air pollution has contributed to the development and progression of heart-related diseases over the past decades. However, little experimental data and few studies of SO , NO , and PM co-exposure in animals exist; therefore, the relevant mechanisms underlying this phenomenon are unclear. An important characteristic of air pollution is that co-exposure persists at a low concentration throughout a lifetime. In the present study, we treated adult mice with SO , NO , and PM at various concentrations (0.5 mg/m SO , 0.2 mg/m NO 6 h/d, with intranasal instillation of 1 mg/kg PM every other day during these exposures; or 3.5 mg/m SO , 2 mg/m NO 6 h/d, and 10 mg/kg PM for 28 d). Blood pressure (BP), heart rate (HR), histopathological damage, and inflammatory and endothelial cytokines in the heart were assessed. The results indicate that co-exposure caused endothelial dysfunction by elevating endothelin-1 (ET-1) expression and repressing the endothelial nitric oxide synthase (eNOS) level as well as stimulating the inflammatory response by increasing the levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Additionally, these alterations were confirmed by histological staining. Furthermore, we observed decreased BP and increased HR after co-exposure. Our results indicate that co-exposure to SO , NO , and PM may be a major risk factor for cardiac disease and may induce injury to the hearts of mammals and contribute to heart disease. © 2015 Wiley Periodicals, Inc. Environ Toxicol 31: 1996-2005, 2016.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5

Zhang

et al. 2015

Environ. Toxicol.

View full text Add to dashboard Cite

show abstract

“…Takayasu arteritis (TAK) is a chronic inflammatory disease that mainly involves the aorta and its major branches [ 1 ]. Previous studies reported higher prevalence of traditional cardiovascular risk factors in patients with TAK than in healthy controls [ 2 – 4 ]. Moreover, accelerated atherosclerosis has been clearly documented in TAK [ 5 , 6 ], and the incidence of cardiovascular events is higher in patients with TAK than in age- and sex-matched controls [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

Kwon

Park

et al. 2020

Arthritis Res Ther

View full text Add to dashboard Cite

Background: To identify disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis (TAK). Methods: Patients with TAK who fulfilled the American College of Rheumatology 1990 criteria for the classification of TAK and were followed up between 2006 and 2019 were included. Traditional cardiovascular risk factors and TAK disease-specific factors at the index date and incident cardiovascular events during the follow-up were retrospectively assessed. To estimate the risk of cardiovascular events according to TAK disease-specific factors, Cox regression analysis with adjustment for traditional cardiovascular risk factors was performed. Results: Of the total 207 patients with TAK, cardiovascular events occurred in 41 (19.8%) patients. Compared with patients who did not develop cardiovascular events, patients who developed cardiovascular events were older (38.5 ± 13.4 years vs. 43.6 ± 11.8 years, p = 0.028), more commonly had diabetes mellitus (6.6% vs. 19.5%, p = 0.029), had lower high-density lipoprotein cholesterol (57.3 ± 17.1 mg/dl vs. 51.2 ± 15.7 mg/dl, p = 0.040), more commonly had type V vascular involvement (33.1% vs. 63.4%, p 0.001), and less commonly received methotrexate (65.1% vs. 43.9%, p = 0.013). In Cox regression analysis, type V vascular involvement was significantly associated with increased risk of cardiovascular events (adjusted HR 2.852, 95% CI 1.474-5.518, p = 0.002), whereas the use of methotrexate was associated with reduced risk of cardiovascular events (adjusted HR 0.515, 95% CI 0.268-0.993, p = 0.047). Conclusion: Type V vascular involvement was associated with increased risk of cardiovascular events, while the use of methotrexate was associated with reduced risk of cardiovascular events, in patients with TAK.

show abstract

“…In the majority of papers, patients with active disease presented with higher ESR and CRP levels as compared with patients with stable/inactive disease (ESR ranged 5–115 mm/hour vs 1–43 mm/hour and CRP ranged 0.1–99.1 mg/dL vs 0.06–7.77 mg/dL for active vs stable disease, respectively). Nevertheless, 28.5% of patients classified as being in remission (National Institutes of Health (NIH) criteria) may present with elevated CRP and 23.8% with elevated ESR23 (overall LoE 4) 23–29…”

Section: Resultsmentioning

confidence: 99%

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo collect available evidence on management of large vessel vasculitis to inform the 2018 update of the EULAR management recommendations.MethodsTwo independent systematic literature reviews were performed, one on diagnosis and monitoring and the other on drugs and surgical treatments. Using a predefined PICO (population, intervention, comparator and outcome) strategy, Medline, Embase and Cochrane databases were accessed. Eligible papers were reviewed and results condensed into a summary of findings table. This paper reports the main results for Takayasu arteritis (TAK).ResultsA total of 287 articles were selected. Relevant heterogeneity precluded meta-analysis. Males appear to have more complications than females. The presence of major complications, older age, a progressive disease course and a weaker inflammatory response are associated with a more unfavourable prognosis. Evidence for details on the best disease monitoring scheme was not found. High-quality evidence to guide the treatment of TAK was not found. Glucocorticoids are widely accepted as first-line treatment. Conventional immunosuppressive drugs and tumour necrosis factor inhibitors were beneficial in case series and uncontrolled studies. Tocilizumab failed the primary endpoint (time to relapse) in a randomised controlled clinical trial; however, results still favoured tocilizumab over placebo. Vascular procedures may be required, and outcome is better when performed during inactive disease.ConclusionsEvidence to guide monitoring and treatment of patients with TAK is predominantly derived from observational studies with low level of evidence. Therefore, higher-quality studies are needed in the future.

show abstract

Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients

Cited by 22 publications

References 27 publications

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5

Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

Contact Info

Product

Resources

About

Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients

Cited by 22 publications

References 27 publications

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO2, NO2, and PM2.5

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO2, NO2, and PM2.5

Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis

Contact Info

Product

Resources

About

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5

Inflammatory response and endothelial dysfunction in the hearts of mice co-exposed to SO₂, NO₂, and PM_2.5